Nasdaq Welcomes ObsEva SA (Nasdaq: OBSV) to The Nasdaq Stock Market

NEW YORK, Jan. 26, 2017 (GLOBE NEWSWIRE) — ObsEva SA (Nasdaq:OBSV), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/940124aa-6457-4a63-9951-bc3cc52cbb31

Founded in Switzerland in November 2012, ObsEva is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. There are millions of women of reproductive age affected by conditions such as endometriosis, uterine fibroids and preterm labor, or that require in vitro fertilization, or IVF, to conceive. The company’s goal is to build the leading women’s reproductive health and pregnancy company focused on conditions where current treatment options are limited and significant unmet needs exist.

“ObsEva is honored to be one of the few publicly traded companies devoted to the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy,” said Ernest Loumaye, MD, PhD, Co-Founder and Chief Executive Officer of ObsEva. “I would like to thank the NASDAQ team for their tremendous support on this journey and their partnership as we prepared for today. ObsEva’s NASDAQ listing and expansion into the United States is a significant accomplishment and exceptional milestone for the entire team.”

“As the leading exchange for many successful health care companies, we are proud to be the listing partner of ObsEva as they continue to drive forward the development of innovative women’s reproductive health and pregnancy therapeutics,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and approximately 18,000 corporate clients. To learn more, visit: business.nasdaq.com.

– NDAQG –

Media Relations Contacts: Stephanie Lowenthal  (646) 441-5073 [email protected]  Emily Pan (646) 441-5120 [email protected]